Topical use of hormone injection in the treatment of neuroinflammatory paralytic strabismus

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024286

Enrollment

Unknown

Registered

2019-07-05

Start date

2019-08-01

Completion date

Unknown

Last updated

2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroinflammatory paralytic strabismus

Interventions

Local injection of hormone:Local injection of hormone

Systemic use of hormone group:Systemic use of hormone group

Eligibility

Sex/Gender

All

Age

4 Years to 75 Years

Inclusion criteria

Inclusion criteria: From August 2019 to August 2021, patients who came to our hospital for neuroinflammatory paralytic strabismus were diagnosed according to typical symptoms and signs and auxiliary examinations, such as the same machine, prism, four-hole lamp, Hes screen.

Exclusion criteria

Exclusion criteria: Those with systemic symptoms (with hypothyroidism below the neck), who are not supportive of the treatment plan, are unable to complete the follow-up on time.

Design outcomes

Primary

Measure	Time frame
Squint degree;	—

Secondary

Measure	Time frame
vision;intraocular pressure;	—

Countries

China

Contacts

Public ContactMinghua Shi

Wuhan Aier Eye Hospital (Hanyang)

13995559689@163.com+86 13995559689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026